1. Home
  2. IEX vs VTRS Comparison

IEX vs VTRS Comparison

Compare IEX & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEX Corporation

IEX

IDEX Corporation

N/A

Current Price

$223.17

Market Cap

17.6B

Sector

Industrials

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$16.72

Market Cap

18.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IEX
VTRS
Founded
1987
1961
Country
United States
United States
Employees
N/A
30000
Industry
Fluid Controls
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6B
18.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
IEX
VTRS
Price
$223.17
$16.72
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$229.63
$13.50
AVG Volume (30 Days)
482.9K
6.7M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.31%
3.21%
EPS Growth
N/A
N/A
EPS
3.54
0.05
Revenue
$3,457,500,000.00
$14,299,900,000.00
Revenue This Year
$4.09
$4.41
Revenue Next Year
$4.36
$1.96
P/E Ratio
$62.95
$333.00
Revenue Growth
5.77
N/A
52 Week Low
$158.19
$9.43
52 Week High
$243.80
$18.39

Technical Indicators

Market Signals
Indicator
IEX
VTRS
Relative Strength Index (RSI) 41.37 50.30
Support Level $216.54 $15.89
Resistance Level $223.85 $17.22
Average True Range (ATR) 4.36 0.41
MACD -0.83 0.00
Stochastic Oscillator 20.34 45.69

Price Performance

Historical Comparison
IEX
VTRS

About IEX IDEX Corporation

Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: